Curatis Holding（CURN）株式概要キュラティス・ホールディング社は、希少疾患や専門医療疾患の予防、診断、治療のための医薬品の買収、開発、商業化に従事しています。 詳細CURN ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績0/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より88.1%で取引されている 収益は年間16.44%増加すると予測されています 過去 1 年間で収益は56.6%増加しましたリスク分析Swiss市場と比較して、過去 3 か月間の株価の変動が非常に大きいキャッシュランウェイが1年未満である すべてのリスクチェックを見るCURN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCHF Current PriceCHF 23.90144.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-49m23m2016201920222025202620282031Revenue CHF 23.1mEarnings CHF 3.4mAdvancedSet Fair ValueView all narrativesCuratis Holding AG 競合他社BioVersysSymbol: SWX:BIOVMarket cap: CHF 157.9mNewron PharmaceuticalsSymbol: SWX:NWRNMarket cap: CHF 281.0mCosmoSymbol: SWX:COPNMarket cap: CHF 1.3bAddex TherapeuticsSymbol: SWX:ADXNMarket cap: CHF 5.5m価格と性能株価の高値、安値、推移の概要Curatis Holding過去の株価現在の株価CHF 23.9052週高値CHF 27.9052週安値CHF 10.05ベータ-0.831ヶ月の変化-2.05%3ヶ月変化37.36%1年変化78.36%3年間の変化n/a5年間の変化n/aIPOからの変化59.33%最新ニュースお知らせ • Sep 18Curatis Holding AG Announces FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 - Corticorelin on Track for Phase 3Curatis Holding AG received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary to solid tumor brain metastases. The Phase 3 will utilize an adaptive trial design consisting of a dose optimization lead-in and confirmatory segment. PTBE occurs in association with many primary and metastatic (secondary) brain tumors, often in connection with metastases caused by lung cancer, breast cancer, melanoma and colorectal cancer. PTBE results in impairment of brain function due to the accumulation of extracellular fluid around the tumor and can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status. Standard of care treatment for PTBE is the use of corticosteroids which frequently have serious side effects such as severe myopathy, impared glucose metabolism, muscle wasting, abnormal weight gain, oeoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. Additionally, corticosteroids can also counteract certain cancer therapies such as chemotherapy or emerging immunotherapies. In the US alone, more than 150,000 patients suffer from PTBE.お知らせ • May 23Curatis Holding AG Announces Executive ChangesCuratis Holding AG announced strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC). Kirsty Crame, MD, was educated at the University of Amsterdam as a Doctor of Medicine. She has more than 12 years of experience in clinical development, of which more than 10 years have been in the field of immuno-oncology in a variety of indications for rare and non-rare diseases. Kirsty was previously a member of the Executive Committee and Vice President of Clinical Strategy and Development at Medigene, a German biotech company specializing in the development of highly innovative, T-cell receptor-directed cancer therapies. Prior to that, she was Director of Clinical Development at Gadeta, a Dutch company specializing in the development of novel immunotherapies. Kirsty will support Curatis in the preparation and conduct of the pivotal Phase 3 study with C-PTBE-01 and also brings extensive experience in regulatory affairs. Timm Trenktrog, PhD, worked for Actelion Pharmaceuticals Ltd. in Switzerland for more than 19 years, most recently as Vice President and Head of Technical Operations on the Executive Board. As a leading pharmaceutical expert, he lectured for over 10 years at the ETH Zurich on quality, production and technical development. Timm will support Curatis in the area of technical development and manufacturing (CMC) for C-PTBE-01 to ensure smooth production and the highest quality of the active ingredient, dosage form and final product.お知らせ • Mar 11Curatis Announces Formation of Distinguished Advisory BoardCuratis Holding announced the formation of an Advisory Board comprised of four internationally recognized experts across multiple medical and scientific disciplines. The board brings together leaders in pediatric oncology, neurology, drug development, and biochemistry to guide Curatis's research initiatives and strategic direction. The Advisory Board includes: Stewart Goldman, MD – An internationally renowned pediatric oncologist who serves as Chair of the Department of Child Health at the University of Arizona College of Medicine - Phoenix and Senior Vice President of Research at Phoenix Children's. Dr. Goldman oversees more than 700 research studies and is an accomplished leader in brain tumor research with over 170 peer-reviewed publications. Previously, he spent 23 years at Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine. Prof. Dr. Andreas Gantenbein – Past-president of the Swiss Headache Society and a distinguished neurologist whose research focuses on clinical studies including medication overuse headache, menstrual migraine, and CGRP-antibodies. Prof. Gantenbein began his career as a clinical research fellow in the Headache Group at Queen Square, London, and has since published more than 100 articles in peer-reviewed journals. He currently runs a private practice in Bülach after serving as Chief Physician of Neurology at the rehabilitation center RehaClinic Bad Zurzach. Dr. Anthony Man, B.Med Sci, MB, BS, FRCP (UK) – A physician with over 35 years of experience in international clinical research and drug development across multiple therapeutic areas. Dr. Man has contributed to more than 30 successful new drug applications and has held senior management positions at pharmaceutical companies including Lederle, Roche, Ciba Geigy, and Novartis. He also served as Chief Development Officer and Chief Executive Officer of Basilea Pharmaceutica from 2000-2013. Prof. Dr. Arnim Pause, M.Sc., Ph.D. – A Professor of Biochemistry at McGill University'sGoodman Cancer Institute and the Department of Biochemistry in Montreal, Canada. Prof. Pause is also Senior Director of Research at Kreamedica Inc. and has authored over 90 high-impact peer-reviewed publications, book chapters, and patents. With experience in both academia and industry, his research expertise spans molecular medicine with a focus on cancer biology.お知らせ • Nov 14Curatis Holding AG to Apply for A Biologic License for C-PTBE-01 in the USACuratis Holding AG has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years.お知らせ • May 31Curatis Holding AG, Annual General Meeting, Jun 21, 2024Curatis Holding AG, Annual General Meeting, Jun 21, 2024, at 14:00 W. Europe Standard Time. Location: pratteln Switzerlandお知らせ • Jan 29Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction.Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction on January 29, 2024. Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share (into one newly issued Kinarus Holding share, whereby the consideration consists of approx. 14x the number of outstanding Kinarus shares (the “Consideration Shares”). Kinarus Holding shall be renamed to Curatis Holding AG with a proposed change of ticker symbol to (“CURE”) and the domicile of the Company be moved to Liestal, Basel-Landschaft. All shareholders of Curatis shall contribute and exchange their Curatis Shares (as a contribution in kind in an ordinary capital increase of Kinarus Holding) into Consideration Shares in the context of this contemplated transaction. In addition to the Combination Transaction, Kinarus Holding and Curatis have placed an offer with the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to purchase selected assets (patents, products and precursor, intellectual property as well as data of Kinarus AG in Liquidation relating to their lead product candidate, KIN001) from the bankruptcy estate of Kinarus AG in Liquidation, a 100% subsidiary of Kinarus Holding. Concurrently, also subject to approval by the Extraordinary General Meeting of Kinarus Holding, the Company will reduce the nominal value of the New Kinarus Shares from CHF 44.80 post Reserve Share Split to CHF 0.10 with a swap of CHF 44.70 in nominal amount per New Kinarus Share from share capital into statutory capital reserves. As a result, the nominal value per New Kinarus Shares will be CHF0.10. The final details of the Reverse Share Split transaction are expected to be announced together with the invititation to the Extraordinary General Meeting of Kinarus Holding in February 2024. As a result of all these transactions, the currently outstanding share capital of Kinarus Holding will be aggregated in the ratio 4,480:1, leading to 292,450 New Kinarus Shares post Reverse Share Split. In the context of the closing of the Combination Transaction, 4,093,916 New Kinarus Shares will be issued and used to settle the Combination Transaction with a share exchange ratio 1:1 for Curatis shares. Post the implementation of the Transaction, Kinarus Holding is expected to have an issued share capital of CHF438,636.60, divided into 4,386,366 New Kinarus Holding shares with nominal value CHF0.10 each. In addition, Kinarus Holding will have a maximum of approx. 850,000 options outstanding to third parties to purchase New Kinarus Shares so that the maximum total amount of fully diluted number of New Kinarus Shares outstanding is approximately 5,250,000. In the context of the Combination Transaction, it is envisaged that an up to CHF 5.5 milllion financing transaction in the form of a Mandatory Exchangeable Loan Note issued by Curatis (the “Financing Round”) is implemented. The closing of the Transaction is subject to various conditions Approval by the courts of Basel-Stadt to revert bankruptcy for Kinarus Holding, Approval of all proposed resolutions to the Extraordinary General Meeting of Kinarus Holding, being scheduled for on or around end of February or early March 2024, Approval by the SIX Swiss Exchange of the listing of the newly issued shares of Kinarus Holding in the frame of the Transaction and Approval by the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to sell the assets, patents, IP and data relating to KIN001 in line with the submitted offer by Kinarus Holding and Curatis. The Transaction is expected to close in Q2 2024.最新情報をもっと見るRecent updatesお知らせ • Sep 18Curatis Holding AG Announces FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 - Corticorelin on Track for Phase 3Curatis Holding AG received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary to solid tumor brain metastases. The Phase 3 will utilize an adaptive trial design consisting of a dose optimization lead-in and confirmatory segment. PTBE occurs in association with many primary and metastatic (secondary) brain tumors, often in connection with metastases caused by lung cancer, breast cancer, melanoma and colorectal cancer. PTBE results in impairment of brain function due to the accumulation of extracellular fluid around the tumor and can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status. Standard of care treatment for PTBE is the use of corticosteroids which frequently have serious side effects such as severe myopathy, impared glucose metabolism, muscle wasting, abnormal weight gain, oeoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. Additionally, corticosteroids can also counteract certain cancer therapies such as chemotherapy or emerging immunotherapies. In the US alone, more than 150,000 patients suffer from PTBE.お知らせ • May 23Curatis Holding AG Announces Executive ChangesCuratis Holding AG announced strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC). Kirsty Crame, MD, was educated at the University of Amsterdam as a Doctor of Medicine. She has more than 12 years of experience in clinical development, of which more than 10 years have been in the field of immuno-oncology in a variety of indications for rare and non-rare diseases. Kirsty was previously a member of the Executive Committee and Vice President of Clinical Strategy and Development at Medigene, a German biotech company specializing in the development of highly innovative, T-cell receptor-directed cancer therapies. Prior to that, she was Director of Clinical Development at Gadeta, a Dutch company specializing in the development of novel immunotherapies. Kirsty will support Curatis in the preparation and conduct of the pivotal Phase 3 study with C-PTBE-01 and also brings extensive experience in regulatory affairs. Timm Trenktrog, PhD, worked for Actelion Pharmaceuticals Ltd. in Switzerland for more than 19 years, most recently as Vice President and Head of Technical Operations on the Executive Board. As a leading pharmaceutical expert, he lectured for over 10 years at the ETH Zurich on quality, production and technical development. Timm will support Curatis in the area of technical development and manufacturing (CMC) for C-PTBE-01 to ensure smooth production and the highest quality of the active ingredient, dosage form and final product.お知らせ • Mar 11Curatis Announces Formation of Distinguished Advisory BoardCuratis Holding announced the formation of an Advisory Board comprised of four internationally recognized experts across multiple medical and scientific disciplines. The board brings together leaders in pediatric oncology, neurology, drug development, and biochemistry to guide Curatis's research initiatives and strategic direction. The Advisory Board includes: Stewart Goldman, MD – An internationally renowned pediatric oncologist who serves as Chair of the Department of Child Health at the University of Arizona College of Medicine - Phoenix and Senior Vice President of Research at Phoenix Children's. Dr. Goldman oversees more than 700 research studies and is an accomplished leader in brain tumor research with over 170 peer-reviewed publications. Previously, he spent 23 years at Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine. Prof. Dr. Andreas Gantenbein – Past-president of the Swiss Headache Society and a distinguished neurologist whose research focuses on clinical studies including medication overuse headache, menstrual migraine, and CGRP-antibodies. Prof. Gantenbein began his career as a clinical research fellow in the Headache Group at Queen Square, London, and has since published more than 100 articles in peer-reviewed journals. He currently runs a private practice in Bülach after serving as Chief Physician of Neurology at the rehabilitation center RehaClinic Bad Zurzach. Dr. Anthony Man, B.Med Sci, MB, BS, FRCP (UK) – A physician with over 35 years of experience in international clinical research and drug development across multiple therapeutic areas. Dr. Man has contributed to more than 30 successful new drug applications and has held senior management positions at pharmaceutical companies including Lederle, Roche, Ciba Geigy, and Novartis. He also served as Chief Development Officer and Chief Executive Officer of Basilea Pharmaceutica from 2000-2013. Prof. Dr. Arnim Pause, M.Sc., Ph.D. – A Professor of Biochemistry at McGill University'sGoodman Cancer Institute and the Department of Biochemistry in Montreal, Canada. Prof. Pause is also Senior Director of Research at Kreamedica Inc. and has authored over 90 high-impact peer-reviewed publications, book chapters, and patents. With experience in both academia and industry, his research expertise spans molecular medicine with a focus on cancer biology.お知らせ • Nov 14Curatis Holding AG to Apply for A Biologic License for C-PTBE-01 in the USACuratis Holding AG has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years.お知らせ • May 31Curatis Holding AG, Annual General Meeting, Jun 21, 2024Curatis Holding AG, Annual General Meeting, Jun 21, 2024, at 14:00 W. Europe Standard Time. Location: pratteln Switzerlandお知らせ • Jan 29Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction.Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction on January 29, 2024. Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share (into one newly issued Kinarus Holding share, whereby the consideration consists of approx. 14x the number of outstanding Kinarus shares (the “Consideration Shares”). Kinarus Holding shall be renamed to Curatis Holding AG with a proposed change of ticker symbol to (“CURE”) and the domicile of the Company be moved to Liestal, Basel-Landschaft. All shareholders of Curatis shall contribute and exchange their Curatis Shares (as a contribution in kind in an ordinary capital increase of Kinarus Holding) into Consideration Shares in the context of this contemplated transaction. In addition to the Combination Transaction, Kinarus Holding and Curatis have placed an offer with the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to purchase selected assets (patents, products and precursor, intellectual property as well as data of Kinarus AG in Liquidation relating to their lead product candidate, KIN001) from the bankruptcy estate of Kinarus AG in Liquidation, a 100% subsidiary of Kinarus Holding. Concurrently, also subject to approval by the Extraordinary General Meeting of Kinarus Holding, the Company will reduce the nominal value of the New Kinarus Shares from CHF 44.80 post Reserve Share Split to CHF 0.10 with a swap of CHF 44.70 in nominal amount per New Kinarus Share from share capital into statutory capital reserves. As a result, the nominal value per New Kinarus Shares will be CHF0.10. The final details of the Reverse Share Split transaction are expected to be announced together with the invititation to the Extraordinary General Meeting of Kinarus Holding in February 2024. As a result of all these transactions, the currently outstanding share capital of Kinarus Holding will be aggregated in the ratio 4,480:1, leading to 292,450 New Kinarus Shares post Reverse Share Split. In the context of the closing of the Combination Transaction, 4,093,916 New Kinarus Shares will be issued and used to settle the Combination Transaction with a share exchange ratio 1:1 for Curatis shares. Post the implementation of the Transaction, Kinarus Holding is expected to have an issued share capital of CHF438,636.60, divided into 4,386,366 New Kinarus Holding shares with nominal value CHF0.10 each. In addition, Kinarus Holding will have a maximum of approx. 850,000 options outstanding to third parties to purchase New Kinarus Shares so that the maximum total amount of fully diluted number of New Kinarus Shares outstanding is approximately 5,250,000. In the context of the Combination Transaction, it is envisaged that an up to CHF 5.5 milllion financing transaction in the form of a Mandatory Exchangeable Loan Note issued by Curatis (the “Financing Round”) is implemented. The closing of the Transaction is subject to various conditions Approval by the courts of Basel-Stadt to revert bankruptcy for Kinarus Holding, Approval of all proposed resolutions to the Extraordinary General Meeting of Kinarus Holding, being scheduled for on or around end of February or early March 2024, Approval by the SIX Swiss Exchange of the listing of the newly issued shares of Kinarus Holding in the frame of the Transaction and Approval by the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to sell the assets, patents, IP and data relating to KIN001 in line with the submitted offer by Kinarus Holding and Curatis. The Transaction is expected to close in Q2 2024.株主還元CURNCH PharmaceuticalsCH 市場7D5.8%2.7%1.8%1Y78.4%31.8%9.1%株主還元を見る業界別リターン: CURN過去 1 年間で31.8 % の収益を上げたSwiss Pharmaceuticals業界を上回りました。リターン対市場: CURN過去 1 年間で9.1 % の収益を上げたSwiss市場を上回りました。価格変動Is CURN's price volatile compared to industry and market?CURN volatilityCURN Average Weekly Movement15.1%Pharmaceuticals Industry Average Movement5.1%Market Average Movement4.5%10% most volatile stocks in CH Market8.2%10% least volatile stocks in CH Market2.4%安定した株価: CURNの株価は、 Swiss市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CURNの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてSwissの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20029Roland Rutschmanncuratis.comキュラティス・ホールディング社は、希少疾患や特殊疾患の予防、診断、治療のための医薬品の買収、開発、商業化に従事している。抗血小板薬、転移性ホルモン受容体陽性乳がん、抗不整脈薬、鼻用オイル、ウィルソン病、青酸中毒、ジゴキシン毒性、降圧薬、膀胱痛症候群／間質性膀胱炎、抗生物質、眼科診断薬、抗ウイルス薬、眼薬／抗生物質、ゲンタマイシンコラーゲンスポンジ、前立腺肥大症、免疫調整薬、てんかん／本態性振戦、甲状腺機能亢進症、免疫調整薬、てんかん／本態性振戦、甲状腺機能亢進症、免疫調整薬、てんかん／本態性振戦、甲状腺機能亢進症免疫調節剤、てんかん・本態性振戦、強心剤、遺伝性チロシン血症1型、消化器、免疫調節剤、強心剤、精神安定剤、ヘリコバクター・ピロリ検査、リン酸結合剤、透析患者用特殊栄養剤、デルマート・コルチコステロイド、鉛・水銀中毒、コルチコスティミュリン、抗霧剤、ハンチントン病に伴う舞踏病、抗てんかん剤。また、小児患者における腫瘍周囲脳浮腫の治療薬として臨床第IIb相試験中のC-PTBE-01、重度の前兆を伴う片頭痛の予防薬として臨床第IIa相試験中のC-AM-01、薬の使い過ぎによる頭痛の治療と予防薬として臨床第IIa相試験中のC-MOH-01、稀な炎症性・線維性疾患の治療薬として臨床第I相試験中のKIN001も開発している。本拠地はスイスのリースタル。もっと見るCuratis Holding AG 基礎のまとめCuratis Holding の収益と売上を時価総額と比較するとどうか。CURN 基礎統計学時価総額CHF 123.20m収益（TTM）-CHF 1.42m売上高(TTM)CHF 10.80m11.4xP/Sレシオ-87.0xPER（株価収益率CURN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CURN 損益計算書（TTM）収益CHF 10.80m売上原価CHF 7.96m売上総利益CHF 2.84mその他の費用CHF 4.26m収益-CHF 1.42m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.27グロス・マージン26.31%純利益率-13.11%有利子負債／自己資本比率0%CURN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 10:20終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Curatis Holding AG 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Bob PoolerValuationLAB AG
お知らせ • Sep 18Curatis Holding AG Announces FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 - Corticorelin on Track for Phase 3Curatis Holding AG received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary to solid tumor brain metastases. The Phase 3 will utilize an adaptive trial design consisting of a dose optimization lead-in and confirmatory segment. PTBE occurs in association with many primary and metastatic (secondary) brain tumors, often in connection with metastases caused by lung cancer, breast cancer, melanoma and colorectal cancer. PTBE results in impairment of brain function due to the accumulation of extracellular fluid around the tumor and can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status. Standard of care treatment for PTBE is the use of corticosteroids which frequently have serious side effects such as severe myopathy, impared glucose metabolism, muscle wasting, abnormal weight gain, oeoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. Additionally, corticosteroids can also counteract certain cancer therapies such as chemotherapy or emerging immunotherapies. In the US alone, more than 150,000 patients suffer from PTBE.
お知らせ • May 23Curatis Holding AG Announces Executive ChangesCuratis Holding AG announced strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC). Kirsty Crame, MD, was educated at the University of Amsterdam as a Doctor of Medicine. She has more than 12 years of experience in clinical development, of which more than 10 years have been in the field of immuno-oncology in a variety of indications for rare and non-rare diseases. Kirsty was previously a member of the Executive Committee and Vice President of Clinical Strategy and Development at Medigene, a German biotech company specializing in the development of highly innovative, T-cell receptor-directed cancer therapies. Prior to that, she was Director of Clinical Development at Gadeta, a Dutch company specializing in the development of novel immunotherapies. Kirsty will support Curatis in the preparation and conduct of the pivotal Phase 3 study with C-PTBE-01 and also brings extensive experience in regulatory affairs. Timm Trenktrog, PhD, worked for Actelion Pharmaceuticals Ltd. in Switzerland for more than 19 years, most recently as Vice President and Head of Technical Operations on the Executive Board. As a leading pharmaceutical expert, he lectured for over 10 years at the ETH Zurich on quality, production and technical development. Timm will support Curatis in the area of technical development and manufacturing (CMC) for C-PTBE-01 to ensure smooth production and the highest quality of the active ingredient, dosage form and final product.
お知らせ • Mar 11Curatis Announces Formation of Distinguished Advisory BoardCuratis Holding announced the formation of an Advisory Board comprised of four internationally recognized experts across multiple medical and scientific disciplines. The board brings together leaders in pediatric oncology, neurology, drug development, and biochemistry to guide Curatis's research initiatives and strategic direction. The Advisory Board includes: Stewart Goldman, MD – An internationally renowned pediatric oncologist who serves as Chair of the Department of Child Health at the University of Arizona College of Medicine - Phoenix and Senior Vice President of Research at Phoenix Children's. Dr. Goldman oversees more than 700 research studies and is an accomplished leader in brain tumor research with over 170 peer-reviewed publications. Previously, he spent 23 years at Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine. Prof. Dr. Andreas Gantenbein – Past-president of the Swiss Headache Society and a distinguished neurologist whose research focuses on clinical studies including medication overuse headache, menstrual migraine, and CGRP-antibodies. Prof. Gantenbein began his career as a clinical research fellow in the Headache Group at Queen Square, London, and has since published more than 100 articles in peer-reviewed journals. He currently runs a private practice in Bülach after serving as Chief Physician of Neurology at the rehabilitation center RehaClinic Bad Zurzach. Dr. Anthony Man, B.Med Sci, MB, BS, FRCP (UK) – A physician with over 35 years of experience in international clinical research and drug development across multiple therapeutic areas. Dr. Man has contributed to more than 30 successful new drug applications and has held senior management positions at pharmaceutical companies including Lederle, Roche, Ciba Geigy, and Novartis. He also served as Chief Development Officer and Chief Executive Officer of Basilea Pharmaceutica from 2000-2013. Prof. Dr. Arnim Pause, M.Sc., Ph.D. – A Professor of Biochemistry at McGill University'sGoodman Cancer Institute and the Department of Biochemistry in Montreal, Canada. Prof. Pause is also Senior Director of Research at Kreamedica Inc. and has authored over 90 high-impact peer-reviewed publications, book chapters, and patents. With experience in both academia and industry, his research expertise spans molecular medicine with a focus on cancer biology.
お知らせ • Nov 14Curatis Holding AG to Apply for A Biologic License for C-PTBE-01 in the USACuratis Holding AG has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years.
お知らせ • May 31Curatis Holding AG, Annual General Meeting, Jun 21, 2024Curatis Holding AG, Annual General Meeting, Jun 21, 2024, at 14:00 W. Europe Standard Time. Location: pratteln Switzerland
お知らせ • Jan 29Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction.Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction on January 29, 2024. Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share (into one newly issued Kinarus Holding share, whereby the consideration consists of approx. 14x the number of outstanding Kinarus shares (the “Consideration Shares”). Kinarus Holding shall be renamed to Curatis Holding AG with a proposed change of ticker symbol to (“CURE”) and the domicile of the Company be moved to Liestal, Basel-Landschaft. All shareholders of Curatis shall contribute and exchange their Curatis Shares (as a contribution in kind in an ordinary capital increase of Kinarus Holding) into Consideration Shares in the context of this contemplated transaction. In addition to the Combination Transaction, Kinarus Holding and Curatis have placed an offer with the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to purchase selected assets (patents, products and precursor, intellectual property as well as data of Kinarus AG in Liquidation relating to their lead product candidate, KIN001) from the bankruptcy estate of Kinarus AG in Liquidation, a 100% subsidiary of Kinarus Holding. Concurrently, also subject to approval by the Extraordinary General Meeting of Kinarus Holding, the Company will reduce the nominal value of the New Kinarus Shares from CHF 44.80 post Reserve Share Split to CHF 0.10 with a swap of CHF 44.70 in nominal amount per New Kinarus Share from share capital into statutory capital reserves. As a result, the nominal value per New Kinarus Shares will be CHF0.10. The final details of the Reverse Share Split transaction are expected to be announced together with the invititation to the Extraordinary General Meeting of Kinarus Holding in February 2024. As a result of all these transactions, the currently outstanding share capital of Kinarus Holding will be aggregated in the ratio 4,480:1, leading to 292,450 New Kinarus Shares post Reverse Share Split. In the context of the closing of the Combination Transaction, 4,093,916 New Kinarus Shares will be issued and used to settle the Combination Transaction with a share exchange ratio 1:1 for Curatis shares. Post the implementation of the Transaction, Kinarus Holding is expected to have an issued share capital of CHF438,636.60, divided into 4,386,366 New Kinarus Holding shares with nominal value CHF0.10 each. In addition, Kinarus Holding will have a maximum of approx. 850,000 options outstanding to third parties to purchase New Kinarus Shares so that the maximum total amount of fully diluted number of New Kinarus Shares outstanding is approximately 5,250,000. In the context of the Combination Transaction, it is envisaged that an up to CHF 5.5 milllion financing transaction in the form of a Mandatory Exchangeable Loan Note issued by Curatis (the “Financing Round”) is implemented. The closing of the Transaction is subject to various conditions Approval by the courts of Basel-Stadt to revert bankruptcy for Kinarus Holding, Approval of all proposed resolutions to the Extraordinary General Meeting of Kinarus Holding, being scheduled for on or around end of February or early March 2024, Approval by the SIX Swiss Exchange of the listing of the newly issued shares of Kinarus Holding in the frame of the Transaction and Approval by the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to sell the assets, patents, IP and data relating to KIN001 in line with the submitted offer by Kinarus Holding and Curatis. The Transaction is expected to close in Q2 2024.
お知らせ • Sep 18Curatis Holding AG Announces FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 - Corticorelin on Track for Phase 3Curatis Holding AG received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary to solid tumor brain metastases. The Phase 3 will utilize an adaptive trial design consisting of a dose optimization lead-in and confirmatory segment. PTBE occurs in association with many primary and metastatic (secondary) brain tumors, often in connection with metastases caused by lung cancer, breast cancer, melanoma and colorectal cancer. PTBE results in impairment of brain function due to the accumulation of extracellular fluid around the tumor and can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status. Standard of care treatment for PTBE is the use of corticosteroids which frequently have serious side effects such as severe myopathy, impared glucose metabolism, muscle wasting, abnormal weight gain, oeoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. Additionally, corticosteroids can also counteract certain cancer therapies such as chemotherapy or emerging immunotherapies. In the US alone, more than 150,000 patients suffer from PTBE.
お知らせ • May 23Curatis Holding AG Announces Executive ChangesCuratis Holding AG announced strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC). Kirsty Crame, MD, was educated at the University of Amsterdam as a Doctor of Medicine. She has more than 12 years of experience in clinical development, of which more than 10 years have been in the field of immuno-oncology in a variety of indications for rare and non-rare diseases. Kirsty was previously a member of the Executive Committee and Vice President of Clinical Strategy and Development at Medigene, a German biotech company specializing in the development of highly innovative, T-cell receptor-directed cancer therapies. Prior to that, she was Director of Clinical Development at Gadeta, a Dutch company specializing in the development of novel immunotherapies. Kirsty will support Curatis in the preparation and conduct of the pivotal Phase 3 study with C-PTBE-01 and also brings extensive experience in regulatory affairs. Timm Trenktrog, PhD, worked for Actelion Pharmaceuticals Ltd. in Switzerland for more than 19 years, most recently as Vice President and Head of Technical Operations on the Executive Board. As a leading pharmaceutical expert, he lectured for over 10 years at the ETH Zurich on quality, production and technical development. Timm will support Curatis in the area of technical development and manufacturing (CMC) for C-PTBE-01 to ensure smooth production and the highest quality of the active ingredient, dosage form and final product.
お知らせ • Mar 11Curatis Announces Formation of Distinguished Advisory BoardCuratis Holding announced the formation of an Advisory Board comprised of four internationally recognized experts across multiple medical and scientific disciplines. The board brings together leaders in pediatric oncology, neurology, drug development, and biochemistry to guide Curatis's research initiatives and strategic direction. The Advisory Board includes: Stewart Goldman, MD – An internationally renowned pediatric oncologist who serves as Chair of the Department of Child Health at the University of Arizona College of Medicine - Phoenix and Senior Vice President of Research at Phoenix Children's. Dr. Goldman oversees more than 700 research studies and is an accomplished leader in brain tumor research with over 170 peer-reviewed publications. Previously, he spent 23 years at Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine. Prof. Dr. Andreas Gantenbein – Past-president of the Swiss Headache Society and a distinguished neurologist whose research focuses on clinical studies including medication overuse headache, menstrual migraine, and CGRP-antibodies. Prof. Gantenbein began his career as a clinical research fellow in the Headache Group at Queen Square, London, and has since published more than 100 articles in peer-reviewed journals. He currently runs a private practice in Bülach after serving as Chief Physician of Neurology at the rehabilitation center RehaClinic Bad Zurzach. Dr. Anthony Man, B.Med Sci, MB, BS, FRCP (UK) – A physician with over 35 years of experience in international clinical research and drug development across multiple therapeutic areas. Dr. Man has contributed to more than 30 successful new drug applications and has held senior management positions at pharmaceutical companies including Lederle, Roche, Ciba Geigy, and Novartis. He also served as Chief Development Officer and Chief Executive Officer of Basilea Pharmaceutica from 2000-2013. Prof. Dr. Arnim Pause, M.Sc., Ph.D. – A Professor of Biochemistry at McGill University'sGoodman Cancer Institute and the Department of Biochemistry in Montreal, Canada. Prof. Pause is also Senior Director of Research at Kreamedica Inc. and has authored over 90 high-impact peer-reviewed publications, book chapters, and patents. With experience in both academia and industry, his research expertise spans molecular medicine with a focus on cancer biology.
お知らせ • Nov 14Curatis Holding AG to Apply for A Biologic License for C-PTBE-01 in the USACuratis Holding AG has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years.
お知らせ • May 31Curatis Holding AG, Annual General Meeting, Jun 21, 2024Curatis Holding AG, Annual General Meeting, Jun 21, 2024, at 14:00 W. Europe Standard Time. Location: pratteln Switzerland
お知らせ • Jan 29Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction.Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction on January 29, 2024. Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share (into one newly issued Kinarus Holding share, whereby the consideration consists of approx. 14x the number of outstanding Kinarus shares (the “Consideration Shares”). Kinarus Holding shall be renamed to Curatis Holding AG with a proposed change of ticker symbol to (“CURE”) and the domicile of the Company be moved to Liestal, Basel-Landschaft. All shareholders of Curatis shall contribute and exchange their Curatis Shares (as a contribution in kind in an ordinary capital increase of Kinarus Holding) into Consideration Shares in the context of this contemplated transaction. In addition to the Combination Transaction, Kinarus Holding and Curatis have placed an offer with the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to purchase selected assets (patents, products and precursor, intellectual property as well as data of Kinarus AG in Liquidation relating to their lead product candidate, KIN001) from the bankruptcy estate of Kinarus AG in Liquidation, a 100% subsidiary of Kinarus Holding. Concurrently, also subject to approval by the Extraordinary General Meeting of Kinarus Holding, the Company will reduce the nominal value of the New Kinarus Shares from CHF 44.80 post Reserve Share Split to CHF 0.10 with a swap of CHF 44.70 in nominal amount per New Kinarus Share from share capital into statutory capital reserves. As a result, the nominal value per New Kinarus Shares will be CHF0.10. The final details of the Reverse Share Split transaction are expected to be announced together with the invititation to the Extraordinary General Meeting of Kinarus Holding in February 2024. As a result of all these transactions, the currently outstanding share capital of Kinarus Holding will be aggregated in the ratio 4,480:1, leading to 292,450 New Kinarus Shares post Reverse Share Split. In the context of the closing of the Combination Transaction, 4,093,916 New Kinarus Shares will be issued and used to settle the Combination Transaction with a share exchange ratio 1:1 for Curatis shares. Post the implementation of the Transaction, Kinarus Holding is expected to have an issued share capital of CHF438,636.60, divided into 4,386,366 New Kinarus Holding shares with nominal value CHF0.10 each. In addition, Kinarus Holding will have a maximum of approx. 850,000 options outstanding to third parties to purchase New Kinarus Shares so that the maximum total amount of fully diluted number of New Kinarus Shares outstanding is approximately 5,250,000. In the context of the Combination Transaction, it is envisaged that an up to CHF 5.5 milllion financing transaction in the form of a Mandatory Exchangeable Loan Note issued by Curatis (the “Financing Round”) is implemented. The closing of the Transaction is subject to various conditions Approval by the courts of Basel-Stadt to revert bankruptcy for Kinarus Holding, Approval of all proposed resolutions to the Extraordinary General Meeting of Kinarus Holding, being scheduled for on or around end of February or early March 2024, Approval by the SIX Swiss Exchange of the listing of the newly issued shares of Kinarus Holding in the frame of the Transaction and Approval by the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to sell the assets, patents, IP and data relating to KIN001 in line with the submitted offer by Kinarus Holding and Curatis. The Transaction is expected to close in Q2 2024.
